Genesis Molecular AI

Genesis develops AI models for molecular physics, including Pearl, a diffusion model, and specialized LLMs and RL methods for drug discovery.

GEMS unifies foundation models, agents, and chemistry tools so chemists run the full design cycle in one place: generate, predict, interrogate, decide.

Genesis partners with Gilead and Incyte to apply its GEMS platform to hard-to-drug targets, advancing oral small molecule programs.

The page describes a NeurIPS 2026 paper co-authored by Caltech and Genesis Molecular AI.

Modern AI models enable cofolding, predicting protein structures alongside bound molecules like drug candidates. Genesis’s Pearl model exemplifies this approach.

Incyte and Genesis Molecular AI expanded their collaboration to use AI for discovering novel molecules, incorporating Incyte’s proprietary experimental data for large-scale foundation model training.

Drug discovery involves designing molecules to fit dynamic protein targets. Accurate protein-ligand structure prediction could enable faster, rational drug design.

Latest news, press, and publications from Genesis, including the Pearl launch and announcements with Gilead, Incyte, and NVIDIA.

Genesis seeks team members in AI research, drug discovery, engineering, and operations to advance small molecule drug development for severe diseases.

The company uses AI in small-molecule drug discovery for severe diseases and lists roles in AI research, drug discovery, engineering, and operations.

Evan is the CEO and co-founder of Genesis, which he established in 2019 to advance AI and simulation research from Vijay Pande’s lab at Stanford University. His work includes PotentialNet, a physics-based ML framework for challenging drug targets.

Greg invests in life science and healthcare teams at Menlo Ventures, with a focus on therapeutic platforms, digital health, and transformative technologies. He previously led startups and held executive roles in life science and digital health.

Guido Appenzeller invests in AI, infrastructure, open-source technology, and silicon at Andreessen Horowitz. He previously served as CTO for Intel’s Data Platforms Group and held product leadership roles at Yubico and VMware.

James Watson leads business and corporate development for life sciences at Andreessen Horowitz, supporting strategic and financing initiatives. He previously held leadership roles in venture-backed biotech companies, including Carmot Therapeutics.

Genesis pairs AI researchers and simulation experts with drug hunters and is backed by AI and life science investors.

Reach Genesis for business development, media inquiries, or general questions. Offices in San Mateo, San Diego, and New York.

Reach Genesis for business development, media inquiries, or general questions. Offices in San Mateo, San Diego, and New York.

Genesis combines frontier AI with drug discovery experts to develop small molecule medicines, leveraging Pearl and GEMS in collaboration with Gilead and Incyte.

Genesis combines AI and drug hunters to discover small-molecule medicines, builds on Pearl and GEMS, and has partnered with Gilead and Incyte.

Incyte and Genesis Therapeutics enter a strategic AI-focused research collaboration to discover and develop novel small-molecule medicines. The companies will use Genesis’ GEMS platform to research, discover, and develop the medicines, and Genesis receives a $30 million upfront payment.

Feb 2025BioSpaceNews article

Gilead Sciences and Genesis Therapeutics enter a strategic collaboration to discover and develop novel small-molecule therapies using Genesis’ GEMS AI platform. The agreement gives Gilead exclusive development and commercialization rights to the novel therapies discovered and developed through this collaboration.

Sep 2024Gilead SciencesNews article

Genesis Therapeutics closes an oversubscribed $200 million Series B financing to advance its AI-enabled pipeline into clinical development. The financing will also support expansion of its GEMS platform against previously undruggable targets.

Aug 2023Pharm ExecNews article

Genesis Therapeutics completes a $52 million Series A financing to expand its AI-driven drug-discovery platform. Rock Springs Capital leads the round, with participation from Andreessen Horowitz, T. Rowe Price, Menlo Ventures, and Radical Ventures.

Dec 2020BioSpaceNews article